number of access : ?
number of downloads : ?
ID 115625
Author
Keywords
Insulin icodec
Phase II clinical trial
Treating to target in type 2 diabetes (4-T) trial
Insulin glargine
Food and drug administration (FDA)
Content Type
Journal Article
Description
There was a new report for once-weekly Novo Nordisk's insulin icodec. After subcutaneous injection, the blood concentration reaches its maximum in 16 hours, and the half-life is about 1 week. The phase II clinical trial showed i) subjects were 247 type 2 diabetes, 59.6 ± 8.9 years, BMI 31.3 ± 4.6, HbA1c 8.0 ± 0.7%, FPG 181 ± 42 mg/dL, ii) For 26 weeks, HbA1c improved from 8.1% to 6.7% in group Ico and from 8.0% to 6.9% in group Gla with no significant difference, iii) significantly markers superior to Group Ico included changes in the mean daily glucose profile and time period of 70-140 mg/dL by CGM. Insulin icodec will hopefully develop smooth next phase trial.
Journal Title
Journal of Diabetes, Obesity & Metabolism
Publisher
Yumed Text
Volume
3
Issue
2
Start Page
e105
Published Date
2020-12-24
Rights
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License(https://creativecommons.org/licenses/by-nc-sa/4.0/).
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences